India ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

India Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The India Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $538 Mn in 2022 and is projected to reach $1,195 Mn in 2030, exhibiting a CAGR of 10.5% during the forecast period. The Ministry of Health and Family Welfare received $10.79 Bn from the Union Budget 2023-24, a rise of almost 3.4% from $10.43 Bn in FY 2022-23. Amounting to 21% less than the $4.48 Bn allotted in 2022-23, the National Health Mission (NHM) received $3.52 Bn. This was mainly brought on by the Pradhan Mantri Swasthya Suraksha Yojana's (PMSSY) significant 66.4 % decrease in funding from $1.21 Bn in the previous budget to $0.40 Bn this year. However, as part of other Central Sector Expenditures, a sum of $0.82 Bn has been reallocated for the setup costs of 22 new AIIMS.

One of the most common neurological developmental disorders affecting children, teenagers, and even adults is attention-deficit hyperactivity disorder (ADHD). It shows up as concentration problems, hyperactivity, and impulsivity. Impulsivity and ADHD can interfere with a student's ability to compete in sports, achieve objectives, and do well in academic settings. Numerous observational studies have been conducted over the past ten years to gauge the prevalence of ADHD in children in India. However, the prevalence reported in a number of studies is restricted to a particular geographic area, and the prevalence is also found to vary widely between studies. For example, the prevalence in individuals aged between 6 and 18 years in Kashmir was 4.31%, whereas, in individuals aged between 6 and 12 years in Bangalore, it was 2.3%, in individuals aged between 6 and 18 years in Odisha was 3.66%, in individuals aged between 10 and 16 years in New Delhi was 6.4%, in individuals aged between 6 and 11 years in Assam was 12.66%. Recognizing the prevalence of ADHD in kids and teenagers will aid clinicians in making an early evaluation, which will lessen the negative effects of this syndrome.

Treatments for ADHD symptoms aim to improve symptoms by balancing and enhancing hormones. About 70-80% of individuals who take stimulant medications report success. They can be applied to both mild and serious ADHD symptoms.

 For children older than 3 and older than 6, respectively, certain stimulants are permitted. Children, teenagers, and adults who struggle at work, home, or school can benefit from these medications. Stimulants can help concentrate better and block out distractions. Amphetamine, also known as Adderall, Adzenys, and Dextroamphetamine, also known as Dexedrine, are a few examples of stimulants. Non-stimulants can help to reduce side effects when the side effects from the stimulants are severe. Here are a few instances of non-stimulants: Atomoxetine or bupropion is the first non-stimulant medication that the FDA has authorized for use in treating ADHD in children, adolescents, and adults. The drug clonidine hydrochloride (Kapvay) has also received approval. It may be recommended for use both alone and with another stimulant. Guanfacine (Intuniv) is a medication that can be used by kids and teenagers between the ages of 6 and 17.

Although there is a significant amount of ADHD prevalence in India, parents are still reluctant to give their kids ADHD medications. According to a study titled a preliminary study of factors influencing adherence to medication in clinic children with attention-deficit/hyperactivity disorder, 83.3% of those who are given ADHD medications stop taking them within the first month.

Market Dynamics

Market Growth Drivers

The market for ADHD therapeutics in India has an enormous amount of potential given that the prevalence of ADHD is much higher than the global average. There is a rising need for improved healthcare facilities and services in India as people's disposable income rises. This is anticipated to result in a rise in the use of ADHD therapeutics, which will fuel the market's expansion. In order to increase access to healthcare services, the Indian government has actively supported the healthcare industry and enacted a number of programs. This is anticipated to fuel the India ADHD therapeutics market's expansion.

Market Restraints

Parents of ADHD patients are reluctant to continue their child's therapy due to side effects, ineffectiveness, hospital issues, and concerns about the child developing an addiction, which is limiting the India ADHD therapeutics market's expansion.

Although there has been a rise in awareness of ADHD in India, the condition is still not well understood. The lack of awareness of ADHD symptoms among many parents, caregivers, and medical workers can delay diagnosis and treatment. In India, contempt related to mental health, including ADHD, is still very strong. This may discourage people with ADHD from getting care or from speaking up about their condition, which may restrain the India ADHD therapeutics market's expansion.

Competitive Landscape

Key Players

• Chiral Drugs (IND)
• CTX Lifesciences (IND)
• KLM Laboratories (IND)
• Actiza Pharmaceutical (IND)
• Ayursun Pharma (IND)
• Eli Lily
• Pfizer
• Johnson & Johnson
• Lupin
• Shire
• Mallinckrodt
• Prude Pharma
• NEOS Therapeutics

Healthcare Policies and Regulatory Landscape

The National Regulatory Authority (NRA) of India is the Central Drugs Standard Control Organization (CDSCO) under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. The Drugs & Cosmetics Act, 1940 and the rules of 1945 have given central and state regulators different duties for the control of drugs & cosmetics. It plans on implementing the Act and its Rules sections consistently in order to protect patients' safety, rights, and well-being by controlling the use of drugs and cosmetics. In order to guarantee the safety, effectiveness, and quality of the medical products produced, imported, and disseminated in the nation, CDSCO is constantly working to increase transparency, accountability, and uniformity in its services.